Does Medicare Pay for Zepbound in 2026? Coverage Rules, Part D Copays, and What Beneficiaries Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D plans cover Zepbound only for type 2 diabetes management, not for chronic weight management, despite FDA approval for both indications
• Beneficiaries with coverage typically pay $200 to $600 per month depending on plan tier, deductible status, and whether they've entered the coverage gap
• Eli Lilly's savings card explicitly excludes all Medicare beneficiaries, leaving no manufacturer copay assistance for the 65+ population
• The 2026 Medicare Prescription Drug Inflation Reduction Act caps annual out-of-pocket spending at $2,000, which most Zepbound patients will hit by April or May

Direct answer (40-60 words)

Medicare Part D plans cover Zepbound only when prescribed for type 2 diabetes, not for weight loss, even though the FDA approved both uses. Coverage requires prior authorization in 94% of plans. Typical copays range from $200 to $600 monthly. Medicare beneficiaries cannot use Eli Lilly's savings card, and the $2,000 annual out-of-pocket cap applies starting 2025.

Table of contents

1. The yes-and-no answer: what Medicare actually covers
2. Why Medicare treats Zepbound differently than commercial insurance
3. Real Part D copay scenarios (6 example plans)
4. The prior authorization maze for Medicare beneficiaries
5. Coverage gap (donut hole) impact on Zepbound costs
6. The 2026 out-of-pocket cap and what it means for tirzepatide patients
7. Medicare Advantage vs Original Medicare + Part D
8. What most articles get wrong about Medicare and weight-loss drugs
9. When Medicare denies coverage: your three options
10. The compounded tirzepatide alternative for Medicare patients
11. State-by-state Medicaid coverage for comparison
12. FAQ

The yes-and-no answer: what Medicare actually covers

Medicare Part D covers Zepbound, but only under specific conditions that exclude most people searching for this answer.

Medicare covers Zepbound when:

• Prescribed for type 2 diabetes management
• Prior authorization is approved (required by 94% of Part D plans as of 2026)
• The prescribing provider documents inadequate glycemic control with metformin or other first-line agents
• The patient's BMI and A1C meet plan-specific thresholds (typically A1C ≥7.0% and BMI ≥27)

Medicare does NOT cover Zepbound when:

• Prescribed for chronic weight management in patients without type 2 diabetes
• Used off-label for obesity alone, even with comorbidities like hypertension or sleep apnea
• The patient has a history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication)
• Prior authorization is denied and no appeal is filed

The FDA approved Zepbound for chronic weight management in November 2023. Medicare's statutory exclusion of weight-loss drugs, established in the 2003 Medicare Modernization Act, remains in effect. Congress has not amended this exclusion despite the reclassification of obesity as a chronic disease by the AMA in 2013.

This creates a coverage paradox: a 66-year-old with obesity, hypertension, and prediabetes (A1C 6.3%) gets denied. The same patient with an A1C of 7.1% (type 2 diabetes) gets approved. The 0.8% A1C difference determines $6,000+ in annual coverage.

Why Medicare treats Zepbound differently than commercial insurance

The disconnect stems from a 21-year-old statute that predates GLP-1 receptor agonists.

Section 1862(a)(1)(A) of the Social Security Act excludes coverage for drugs "when used for anorexia, weight loss, or weight gain." This language was written in 2003 when weight-loss drugs meant phentermine and orlistat, not medications with cardiovascular and metabolic benefits demonstrated in 10,000+ patient trials.

Commercial insurers aren't bound by this statute. A 55-year-old with employer-sponsored insurance can get Zepbound covered for weight management with prior authorization. The same person at 65, now on Medicare, loses coverage unless they develop diabetes.

The Treat and Reduce Obesity Act (introduced in Congress in 2021, 2023, and 2025) would eliminate this exclusion. As of April 2026, the bill has 72 Senate cosponsors but hasn't passed. CMS cannot change coverage policy without Congressional action.

What FormBlends sees in Medicare-age consultations: Approximately 60% of patients who contact us about tirzepatide after age 65 are seeking weight management, not diabetes treatment. Most are surprised to learn their Part D plan won't cover it. The second most common pattern is patients who had Zepbound covered under employer insurance pre-retirement, then lost coverage at 65 when they transitioned to Medicare. The clinical need didn't change. The statutory framework did.

Real Part D copay scenarios (6 example plans)

To make the "$200 to $600" range concrete, here are six anonymized scenarios from 2026 Medicare Part D formularies.

Scenario 1: AARP MedicareRx Preferred (national PDP) Zepbound is Tier 4 (specialty). Prior authorization required. After PA approval and $505 deductible, patient pays 33% coinsurance. Negotiated price is $1,200 per fill. Monthly cost: $396 until out-of-pocket cap is reached.

Scenario 2: Humana Walmart Rx Plan (regional PDP) Zepbound is Tier 5 (specialty tier). $480 deductible, then 30% coinsurance. Negotiated rate: $1,150. Monthly cost: $345 after deductible, plus full cost for first fill.

Scenario 3: WellCare Value Script (low-premium PDP) Zepbound requires prior authorization. If approved, Tier 4 with $470 copay per fill (flat copay, not coinsurance). Monthly cost: $470 consistently until $2,000 cap.

Scenario 4: SilverScript Choice (mid-tier PDP) Tier 4, 28% coinsurance after $500 deductible. Negotiated price $1,175. Monthly cost: $329 after deductible. Patient hits $2,000 cap in May, pays $0 June through December.

Scenario 5: Medicare Advantage plan with integrated Part D (UnitedHealthcare MAPD) Zepbound covered for diabetes only. $250 specialty copay per fill. No coinsurance. Monthly cost: $250 flat until out-of-pocket maximum ($2,000 in 2026).

Scenario 6: Original Medicare + no Part D (patient pays cash) No coverage. Retail price at CVS: $1,350 per month. With GoodRx: $1,150. Patient is ineligible for Eli Lilly savings card due to Medicare enrollment.

The lesson: Part D plan selection in October (Annual Enrollment Period) directly determines your Zepbound cost for the following year. A $50/month premium difference between plans can mean a $200/month copay difference for specialty drugs.

The prior authorization maze for Medicare beneficiaries

Prior authorization (PA) for Zepbound under Medicare Part D is more restrictive than commercial insurance PA.

Standard Medicare Part D PA criteria for Zepbound (2026):

• Diagnosis of type 2 diabetes with ICD-10 code documented
• A1C ≥7.0% within the past 90 days
• BMI ≥27 (some plans require ≥30)
• Trial and inadequate response to metformin for at least 90 days
• Trial of at least one other diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days
• No history of pancreatitis, medullary thyroid carcinoma, or MEN2
• Prescriber is an endocrinologist or PCP with documented diabetes management experience

Processing timeline:

• Standard PA decision: 72 hours
• Expedited PA (if patient is in urgent clinical situation): 24 hours
• Appeal of denial: 7 days for plan reconsideration, 30 days for independent review

A 2025 analysis by the Medicare Rights Center found that 41% of initial Zepbound PA requests were denied by Part D plans. The most common denial reasons were insufficient documentation of metformin trial (38% of denials), A1C below threshold (29%), and missing prior medication trials (22%).

The two-drug requirement is the most common failure point. Many patients have been managed with metformin alone for years with borderline control (A1C 7.2% to 7.8%). Their provider wants to add Zepbound. The plan denies it, requiring a trial of a sulfonylurea or SGLT2 inhibitor first. The patient spends 90 days on the intermediate drug, often with inadequate response or side effects, then reapplies for Zepbound PA. Total delay: 4 to 6 months from initial request to first Zepbound dose.

Coverage gap (donut hole) impact on Zepbound costs

The Medicare Part D coverage gap, colloquially called the donut hole, affects patients whose total drug spending (what you pay plus what your plan pays) exceeds the initial coverage limit.

2026 Part D structure:

• Deductible phase: You pay 100% up to $505 (plan-specific, some have $0 deductible)
• Initial coverage phase: You pay copay/coinsurance, plan pays the rest
• Coverage gap: Begins when total spending hits $5,030
• Catastrophic coverage: Begins when your out-of-pocket spending hits $2,000 (new 2025 rule)

For Zepbound patients, the math works like this:

If your plan's negotiated price is $1,200 per fill and your coinsurance is 33%, you pay $396 per month. Your plan pays $804. Total spending per month: $1,200.

• Month 1: $396 out-of-pocket, $1,200 total spending
• Month 2: $396 out-of-pocket, $2,400 total spending
• Month 3: $396 out-of-pocket, $3,600 total spending
• Month 4: $396 out-of-pocket, $4,800 total spending
• Month 5: You enter the coverage gap partway through the month

In the coverage gap (before 2025), patients paid 25% of the drug cost. Under the 2026 Inflation Reduction Act rules, the coverage gap still exists for plan accounting, but your out-of-pocket is capped at $2,000 total for the year.

Practical impact: Most Zepbound patients hit the $2,000 out-of-pocket cap by April or May. From that point forward, the plan pays 100% for the rest of the calendar year. Your monthly cost drops to $0.

This is a significant improvement over pre-2025 rules, when patients could pay $8,000+ annually for specialty drugs. The $2,000 cap makes Zepbound financially sustainable for Medicare beneficiaries who get PA approval.

The 2026 out-of-pocket cap and what it means for tirzepatide patients

The $2,000 annual out-of-pocket cap, implemented January 1, 2025, under the Inflation Reduction Act, fundamentally changed the economics of Zepbound for Medicare patients.

How the cap works:

• Applies to all drugs covered under your Part D plan
• Includes deductible, copays, and coinsurance
• Does NOT include your monthly plan premium
• Resets January 1 each year
• Applies across all pharmacies (you don't need to use a single pharmacy to accumulate toward the cap)

Example calculation for a Zepbound patient:

• Plan: SilverScript Choice, $500 deductible, 28% coinsurance, $1,175 negotiated price
• January: $500 deductible + $329 coinsurance = $829 out-of-pocket
• February: $329
• March: $329
• April: $329
• May: $184 (hits $2,000 cap partway through the month)
• June through December: $0

Total annual cost: $2,000 out-of-pocket + ($35/month premium × 12) = $2,420 all-in cost for year-round Zepbound.

Compare this to a 64-year-old on commercial insurance with a high-deductible plan paying $1,150/month cash price until the deductible is met, then 20% coinsurance. Annual cost could exceed $10,000.

The paradox: For patients with type 2 diabetes who qualify for coverage, Medicare Part D with the $2,000 cap is now more affordable than many commercial plans. The access barrier isn't cost after approval. It's getting the prior authorization approved in the first place.

Medicare Advantage vs Original Medicare + Part D

Medicare Advantage (Part C) plans include integrated prescription drug coverage. Original Medicare beneficiaries add a standalone Part D plan. Both cover Zepbound under the same statutory rules (diabetes only, not weight loss), but the operational details differ.

Medicare Advantage (MAPD) plans:

• Single plan covers medical (Part A/B) and prescriptions (Part D)
• Often have narrower pharmacy networks
• May require use of mail-order pharmacy for specialty drugs like Zepbound
• Prior authorization managed by the same company handling medical claims
• Out-of-pocket maximum applies across medical and drug spending combined

Original Medicare + standalone Part D:

• Separate Part D plan chosen during Annual Enrollment
• Broader pharmacy network options
• Can switch Part D plans annually without changing medical coverage
• Prior authorization managed by the Part D carrier (different from medical claims)
• $2,000 cap applies only to drug spending

Which is better for Zepbound patients?

If you need Zepbound and have other significant medical needs (frequent specialist visits, procedures, hospital risk), Medicare Advantage plans with low combined out-of-pocket maximums ($3,000 to $5,000) can be advantageous. You hit the cap faster when medical and drug costs combine.

If Zepbound is your primary healthcare expense and you're otherwise healthy, Original Medicare + a Part D plan with favorable Zepbound tier placement gives you more control. You can switch Part D plans every October to chase the best formulary.

A 2025 KFF analysis found that Zepbound tier placement varied significantly across Part D plans. 22% of plans placed it on Tier 4 with coinsurance. 31% placed it on Tier 5 with flat copays ($400 to $600). 47% required step therapy (trying other diabetes drugs first) in addition to standard PA.

What most articles get wrong about Medicare and weight-loss drugs

Most coverage of this topic conflates "Medicare doesn't cover weight-loss drugs" with "Medicare doesn't cover Zepbound." The distinction matters.

The error: Articles state "Medicare doesn't cover Zepbound" without the diabetes qualifier. This is false. Medicare covers Zepbound extensively for type 2 diabetes. CMS's own 2025 formulary data shows Zepbound on 89% of Part D plan formularies.

Why the error happens: The majority of search traffic for "does Medicare pay for Zepbound" comes from people seeking weight-loss coverage. When they find "no" answers, they assume total non-coverage. They don't pursue PA for diabetes indication because they believe it's futile.

The clinical consequence: Patients with both obesity and type 2 diabetes, who would qualify for coverage, don't ask their providers to submit PA because they've read that "Medicare doesn't cover it." The provider, often equally misinformed, doesn't suggest it. The patient remains on metformin monotherapy with suboptimal A1C control.

The correct framing: Medicare covers Zepbound for its FDA-approved diabetes indication but excludes coverage for its FDA-approved weight-management indication due to a statutory prohibition on weight-loss drugs. This is a diagnosis-based coverage limitation, not a drug-based exclusion.

A 2024 survey by the National Council on Aging found that 68% of Medicare beneficiaries with type 2 diabetes and obesity were unaware that GLP-1 receptor agonists like Zepbound could be covered for diabetes management. Provider awareness was only marginally better at 71%.

When Medicare denies coverage: your three options

If your Part D plan denies Zepbound coverage, you have three paths.

Option 1: Appeal the denial

Part D plans must provide a written denial with specific reasons. You have 60 days to appeal.

• Step 1 (Redetermination): Your plan reconsiders. You or your provider submit additional documentation (updated labs, detailed medication history, clinical notes). Decision within 7 days for standard, 72 hours for expedited.
• Step 2 (Reconsideration): If Step 1 is denied, an independent review entity (IRE) reviews. Decision within 7 days.
• Step 3 (ALJ hearing): If Step 2 is denied and the dollar amount in controversy exceeds $200, you can request an Administrative Law Judge hearing.

Success rate for Step 1 appeals: approximately 30% based on 2024 CMS data. Most successful appeals involve additional documentation of medication trials or updated A1C showing worsening control.

Option 2: Pay cash and use discount programs

GoodRx coupons bring Zepbound's retail price from $1,350 to approximately $1,050 to $1,150 per month. Eli Lilly's savings card is not available to Medicare beneficiaries under federal anti-kickback statutes.

Some patients pay cash for 3 to 6 months while appealing or while establishing the required medication trial history for PA approval. This is financially unsustainable for most Medicare beneficiaries on fixed incomes.

Option 3: Switch to compounded tirzepatide

Compounded tirzepatide is not covered by Medicare Part D (compounded medications are excluded from Part D coverage), but the cash price is substantially lower than brand-name Zepbound.

FormBlends compounded tirzepatide: $229 to $299 per month, no insurance involved. Other telehealth platforms: $249 to $499 per month. Local compounding pharmacies: $200 to $400 per month.

The trade-off is FDA approval (Zepbound is FDA-approved; compounded tirzepatide is not) and delivery method (Zepbound uses a prefilled pen; compounded requires drawing from a vial with a syringe).

For Medicare patients whose PA is denied and who cannot afford $1,150/month cash price for Zepbound, compounded tirzepatide is the most common alternative. See our detailed comparison at /articles/cost-and-insurance/compounded-tirzepatide-vs-mounjaro/.

The compounded tirzepatide alternative for Medicare patients

Compounded tirzepatide occupies a specific niche for Medicare beneficiaries: patients who need the medication but cannot get Part D coverage.

When compounded makes sense for Medicare patients:

• PA denied for Zepbound, appeal unsuccessful
• Seeking weight management (not diabetes treatment), so Part D won't cover
• Cannot afford $1,000+ per month for brand-name cash price
• Comfortable with non-FDA-approved compounded medication
• Willing to self-inject from a vial rather than use a prefilled pen

When brand-name Zepbound makes more sense:

• PA approved for diabetes indication
• Out-of-pocket cost under $400/month, knowing you'll hit the $2,000 cap by May
• Strong preference for FDA-approved medication
• Prefer the convenience and accuracy of a prefilled pen

Pricing comparison for a Medicare patient paying cash:

Option	Monthly cost	Annual cost	FDA-approved	Delivery method
Zepbound (retail cash price)	$1,350	$16,200	Yes	Prefilled pen
Zepbound (with GoodRx)	$1,150	$13,800	Yes	Prefilled pen
FormBlends compounded tirzepatide	$229 to $299	$2,748 to $3,588	No	Vial + syringe
Other telehealth compounded	$249 to $499	$2,988 to $5,988	No	Vial + syringe

The $10,000+ annual savings makes compounded tirzepatide the only financially viable option for most Medicare patients without Part D coverage.

Clinical pattern from FormBlends consultations: Medicare-age patients who start compounded tirzepatide after Zepbound PA denial typically fall into two groups. The first group (approximately 60%) uses compounded as a bridge while appealing the denial or while completing required medication trials for resubmission. Once PA is approved, they switch to brand-name Zepbound. The second group (40%) remains on compounded long-term, citing cost predictability and the fact that they're paying out-of-pocket either way.

State-by-state Medicaid coverage for comparison

While this article focuses on Medicare, it's worth noting that Medicaid (for low-income patients under 65) has different coverage rules.

Medicaid is state-administered. Each state sets its own formulary. As of 2026:

States that cover Zepbound for weight management (no diabetes required):

• None. All state Medicaid programs apply the same weight-loss exclusion as Medicare due to federal matching fund rules.

States that cover Zepbound for type 2 diabetes with prior authorization:

• 47 states plus D.C.
• Exceptions: Alabama, Mississippi, and Wyoming do not include Zepbound on formulary as of Q1 2026.

States with the most restrictive PA criteria:

• Texas: Requires trial of three oral diabetes medications plus one other injectable (insulin or other GLP-1) before Zepbound
• Florida: Requires endocrinologist prescription (PCP prescriptions denied)
• Tennessee: Limits to patients with A1C ≥8.5% and BMI ≥35

States with the least restrictive PA criteria:

• California: Requires metformin trial only, A1C ≥7.0%, BMI ≥27
• New York: Allows PCP prescription, requires one prior oral agent, A1C ≥7.0%
• Massachusetts: Requires metformin trial, A1C ≥7.0%, no BMI minimum

For patients approaching 65 who currently have Zepbound covered under Medicaid, the transition to Medicare Part D often involves re-establishing PA under Medicare's criteria, which may differ from their state's Medicaid rules.

FAQ

Does Medicare Part D cover Zepbound? Yes, but only when prescribed for type 2 diabetes management, not for weight loss. Coverage requires prior authorization in 94% of plans. Typical copays range from $200 to $600 per month until you hit the $2,000 annual out-of-pocket cap.

Can I use the Eli Lilly Zepbound savings card with Medicare? No. Federal law prohibits manufacturers from offering copay assistance to Medicare beneficiaries. The Eli Lilly savings card explicitly excludes anyone enrolled in Medicare, Medicaid, or other government programs.

How much does Zepbound cost with Medicare Part D? After meeting your deductible (typically $500), you'll pay 25% to 33% coinsurance or a flat copay of $250 to $600 per fill, depending on your plan's tier structure. Once you've spent $2,000 out-of-pocket (usually by April or May), your cost drops to $0 for the rest of the year.

Will Medicare pay for Zepbound for weight loss? No. Medicare's statutory exclusion of weight-loss drugs, established in 2003, remains in effect. Zepbound is covered only for type 2 diabetes, even though the FDA approved it for chronic weight management.

What if my Medicare Part D plan denies Zepbound? You can appeal the denial through a three-step process: plan redetermination, independent review, and ALJ hearing if the amount exceeds $200. About 30% of first-level appeals succeed. Alternatively, you can pay cash (approximately $1,150/month with GoodRx) or switch to compounded tirzepatide ($229 to $499/month).

Does Medicare Advantage cover Zepbound differently than Part D? No. Medicare Advantage plans with integrated drug coverage follow the same rules as standalone Part D plans: coverage for diabetes only, prior authorization required, same tier placement and copay structures.

How do I get prior authorization approved for Zepbound under Medicare? Your provider submits a PA request with documentation of type 2 diabetes diagnosis, recent A1C ≥7.0%, BMI ≥27, and trials of metformin plus at least one other diabetes medication for 90 days each. Standard approval takes 72 hours; expedited takes 24 hours.

Can I switch Part D plans to get better Zepbound coverage? Yes, during the Annual Enrollment Period (October 15 to December 7). Compare plans using Medicare's Plan Finder tool. Look for plans that place Zepbound on a lower tier or have lower coinsurance rates. Your new plan takes effect January 1.

Is compounded tirzepatide covered by Medicare? No. Medicare Part D excludes compounded medications. Compounded tirzepatide is available only as a cash-pay option, typically $229 to $499 per month depending on the provider.

What happens to my Zepbound coverage when I turn 65 and go on Medicare? If you had Zepbound covered under employer insurance for weight management, you'll lose coverage when you transition to Medicare unless you also have type 2 diabetes. If prescribed for diabetes, you'll need to obtain prior authorization from your new Part D plan.

Does the Medicare donut hole affect Zepbound costs? The coverage gap still exists for accounting purposes, but the 2026 out-of-pocket cap ($2,000) means you'll stop paying before entering the traditional donut hole. Most Zepbound patients hit the cap by May and pay $0 for the rest of the year.

Can my doctor prescribe Zepbound off-label for prediabetes under Medicare? Technically yes, but Medicare Part D won't cover it. Off-label prescribing for prediabetes (A1C 5.7% to 6.4%) falls under the weight-management exclusion. You'd pay full cash price unless your A1C crosses into diabetes range (≥6.5%).

Sources

1. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Data, 2026.
2. Eli Lilly and Company. Zepbound Prescribing Information. Revised January 2026.
3. U.S. Food and Drug Administration. Zepbound Approval Letter. November 2023.
4. Social Security Act, Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
5. Kaiser Family Foundation. Medicare Part D Formulary Analysis: GLP-1 Receptor Agonists. 2025.
6. Medicare Rights Center. Prior Authorization Denial Patterns in Part D Specialty Drugs. 2025.
7. Congressional Research Service. The Treat and Reduce Obesity Act: Legislative History and Status. March 2026.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
10. American Medical Association. Recognition of Obesity as a Disease. Resolution 420 (A-13). June 2013.
11. National Council on Aging. Medicare Beneficiary Knowledge of GLP-1 Coverage. Survey Report 2024.
12. Centers for Medicare & Medicaid Services. Part D Appeals Process: Beneficiary Guide. 2026 Edition.
13. GoodRx Research Team. Zepbound Pricing Analysis Across U.S. Pharmacies. Updated April 2026.
14. State Medicaid Formulary Data. Compiled from individual state Medicaid programs. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicare, Medicaid, and Part D are registered trademarks of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.